Connective Tissue Diseases
Conditions
Brief summary
Anti-Ro52 autoantibodies can be detected in patients with several autoimmune diseases. Clinical significance of anti-Ro52 is controversial. The presence of anti-Ro52 may be a factor associated with disease severity (interstitial lung disease, vasculopathy) and cancers. The aim of this study is to assess interstitial lung disease and vasculopathy prevalence and severity, cancers occurence and others clinical features of connective tissue disease patients with anti-Ro52 autoantibodies.
Interventions
OTHERFollow-up
Clinical data, radiological data and laboratory tests follow-up
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Connective tissue disease (differenciated or not) * Presence of anti-Ro52 antibodies at diagnosis
Exclusion criteria
* Healthy subjects
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ILD prevalence | baseline (J0) | Clinical (cough, dyspnea) and/or radiological (tomodensitometry) data |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ILD severity | baseline (J0) | PFT (pulmonary function test): FVC, FEV1, DLCO (percentages of predicted values) |
| Vasculopathy occurence | baseline (J0) and follow-up | Raynaud disease, digital ulcers or gangrene |
| Cancer occurence | baseline (J0) and follow-up | — |
Countries
France
Contacts
Primary ContactRoland JAUSSAUD, Pr
Backup ContactPaul DECKER, MR
Outcome results
None listed